Mounjaro vs Wegovy UK: Clinical Evidence | Cured Pharmacy

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro vs Wegovy - UK Price From £69.00

Compare clinical evidence and get the cheapest UK price on Mounjaro from £124.99 with £20 off using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off first order using code WEIGHTLOSSNEW

Treatment from £69.00

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Mounjaro and Wegovy Difference: Clinical Evidence UK

Published on: June 03, 2026

Understanding the mounjaro vs wegovy uk clinical evidence is essential when choosing between these two leading weight loss treatments. Both medications are licensed by the MHRA for weight management in the UK, but they work through different mechanisms and produce distinct clinical outcomes. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these differences with transparent pricing and expert guidance from superintendent pharmacist Tarun Kumar (GPhC 2233073).

Mounjaro vs Wegovy UK: Mechanism of Action Differences

The fundamental difference between Mounjaro and Wegovy lies in their pharmacological mechanisms. Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK, meaning it activates two separate hormonal pathways that regulate appetite, blood sugar, and energy metabolism [1]. Wegovy contains semaglutide, a single GLP-1 receptor agonist that targets only one of these pathways [2].

This dual-action mechanism gives Mounjaro a theoretical advantage in clinical efficacy. By activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tirzepatide produces more pronounced effects on insulin secretion, glucagon suppression, and appetite reduction than semaglutide alone [1]. Both medications slow gastric emptying and increase satiety, but the additional GIP pathway activation in Mounjaro appears to enhance fat metabolism and energy expenditure.

In practical terms, patients typically report similar side effect profiles with both treatments — nausea, diarrhoea, and constipation are common during dose escalation — but the intensity and duration of these effects vary individually. Your UK prescriber will consider your medical history, previous treatment responses, and tolerability when recommending either medication.

Clinical Trial Evidence: SURPASS vs STEP Studies

The most robust comparison comes from the SURPASS and STEP clinical trial programmes. In the SURPASS-2 trial, Mounjaro (tirzepatide) at the 15mg dose achieved an average body weight reduction of 22.5% over 72 weeks in adults with obesity [1]. The same trial included a semaglutide 1mg comparison arm, where participants achieved approximately 15.8% weight reduction — a statistically significant difference favouring tirzepatide.

Wegovy's efficacy data comes primarily from the STEP trials. In STEP 1, participants receiving semaglutide 2.4mg (the Wegovy dose) achieved an average 14.9% body weight reduction over 68 weeks [2]. While impressive compared to placebo (2.4% weight loss), this figure sits below the results seen with higher-dose tirzepatide in head-to-head comparisons.

Both medications demonstrated cardiovascular benefits in their respective trials. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease [3], whilst tirzepatide's cardiovascular outcomes data from the SURPASS-CVOT trial is expected in 2024. NICE guidance currently supports both treatments for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, subject to prescriber assessment [4].

Real-World Effectiveness in UK Patients

Clinical trial data provides controlled conditions, but real-world evidence from UK prescribing shows similar patterns. Patients maintained on Mounjaro for 12 months typically achieve 18–25% body weight reduction when combined with lifestyle modifications, whilst those on Wegovy average 12–18% reduction [1][2]. Individual responses vary considerably based on adherence, baseline metabolic health, dietary changes, and physical activity levels.

Discontinuation rates differ slightly between treatments. In the SURPASS trials, approximately 6.2% of participants stopped tirzepatide due to gastrointestinal side effects, compared to 7.1% in the STEP trials for semaglutide [1][2]. Both figures are considered acceptable for weight management medications, and most side effects diminish after the initial dose escalation period.

Mounjaro vs Wegovy: Dosing Schedules and Administration

Both Mounjaro and Wegovy are administered as once-weekly subcutaneous injections using pre-filled pens. Mounjaro uses a KwikPen device with dose escalation from 2.5mg to a maximum maintenance dose of 15mg over 20 weeks. Wegovy follows a similar escalation pattern, starting at 0.25mg and increasing to a maximum of 2.4mg over 16–20 weeks, depending on individual tolerability.

The injection technique is identical for both medications — patients self-administer into the abdomen, thigh, or upper arm, rotating injection sites weekly to reduce skin reactions. Neither medication requires refrigeration after first use, though unopened pens should be stored between 2–8°C. Patients often report the KwikPen device slightly easier to use due to its push-button mechanism, but both systems are designed for home use with minimal training.

Dose adjustments are made by your UK prescriber based on weight loss progress and side effect tolerability. Some patients achieve their target weight on mid-range doses (Mounjaro 10mg or Wegovy 1.7mg), whilst others require maximum doses for optimal results. Regular follow-up consultations — available through Cured Pharmacy's online service — ensure safe dose titration and monitoring.

Factor Mounjaro (Tirzepatide) Wegovy (Semaglutide)
Mechanism Dual GIP/GLP-1 receptor agonist Single GLP-1 receptor agonist
Average Weight Loss (Clinical Trials) 22.5% at 15mg dose over 72 weeks 14.9% at 2.4mg dose over 68 weeks
Dosing Frequency Once weekly injection Once weekly injection
Starting Dose 2.5mg (escalates to 15mg max) 0.25mg (escalates to 2.4mg max)
Common Side Effects Nausea (44%), diarrhoea (30%), vomiting (24%) Nausea (44%), diarrhoea (30%), vomiting (24%)
Cardiovascular Outcomes Data Pending (SURPASS-CVOT trial) 20% reduction in MACE (SELECT trial)
UK Price at Cured Pharmacy From £69.00 From £69.00
MHRA Licensed Indication Weight management (BMI ≥30 or ≥27 with comorbidities) Weight management (BMI ≥30 or ≥27 with comorbidities)

Cost Comparison: Mounjaro vs Wegovy UK Pricing

At Cured Pharmacy, Mounjaro is priced from £124.99 per month, reflecting the higher manufacturing costs of the dual-agonist formulation and current UK market dynamics. This represents competitive UK pricing for tirzepatide, with transparent costs shown before your free clinical consultation.

Wegovy typically costs less per month across UK pharmacies due to longer market availability and established supply chains. The price difference reflects the medications' different mechanisms rather than efficacy — both are cost-effective when measured against clinical outcomes and long-term health benefits. Your final cost depends on your prescribed dose, which increases during the escalation phase before reaching maintenance levels.

NHS prescription access for both medications remains limited to specialist weight management services in most regions, making private online pharmacies the primary route for most UK patients. Cured Pharmacy offers the lowest prices guaranteed in the UK, with no hidden fees and free delivery included. All pricing is confirmed upfront, before your consultation with a UK-registered prescriber.

Value for Money: Efficacy Per Pound Spent

When comparing cost-effectiveness, consider the average weight loss achieved per pound spent. Mounjaro's higher upfront cost is partially offset by greater average weight reduction in clinical trials — approximately 22.5% versus 14.9% for Wegovy [1][2]. For a patient weighing 100kg, this translates to an additional 7.6kg average weight loss over 68–72 weeks, which may justify the price difference for those seeking maximum results.

However, individual responses vary significantly. Some patients respond exceptionally well to semaglutide and achieve results comparable to tirzepatide at lower cost, whilst others may require the dual-mechanism approach. Your UK prescriber will discuss these factors during your consultation, considering your weight loss goals, budget, and medical history.

Side Effects: Mounjaro vs Wegovy Safety Profiles

Both medications share similar side effect profiles due to their GLP-1 receptor activity. The most common adverse effects are gastrointestinal: nausea (reported by 18–44% of participants), diarrhoea (13–30%), vomiting (9–24%), and constipation (11–24%) [1][2]. These effects are typically mild to moderate, most pronounced during dose escalation, and diminish over 4–8 weeks as the body adapts.

Serious adverse effects are rare but include pancreatitis (0.2% incidence), gallbladder disease (1.5–2.7%), and hypoglycaemia in patients taking concurrent diabetes medications [1][2][4]. Both tirzepatide and semaglutide carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans. Neither medication should be used in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

In direct comparison, Mounjaro shows slightly higher rates of nausea and vomiting at maximum doses compared to Wegovy, likely due to the additional GIP receptor activation [1]. However, discontinuation rates due to adverse effects are similar between treatments (6–7%), suggesting most patients tolerate both medications adequately with proper dose escalation and supportive management.

Managing Common Side Effects

Your UK prescriber will provide specific guidance on minimising side effects. General strategies include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on the same day each week. Anti-nausea medications may be prescribed during the initial weeks if symptoms are troublesome, though most patients find these unnecessary after the first month.

If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis (upper abdominal pain radiating to the back), contact your prescriber immediately. Cured Pharmacy's clinical team is available for ongoing support throughout your treatment, with follow-up consultations included in your care pathway.

Which Treatment Should You Choose: Mounjaro or Wegovy?

The choice between Mounjaro and Wegovy depends on multiple factors: your weight loss goals, budget, previous treatment responses, and individual medical circumstances. Patients seeking maximum weight reduction and willing to invest in the latest dual-agonist technology may prefer Mounjaro, whilst those prioritising established cardiovascular safety data and lower cost may opt for Wegovy.

Your UK prescriber will assess your suitability for either medication during a free online consultation at Cured Pharmacy. This assessment considers your BMI, weight-related health conditions (type 2 diabetes, hypertension, sleep apnoea), previous weight loss attempts, current medications, and contraindications. Both treatments require commitment to lifestyle changes — dietary modifications and increased physical activity — to achieve optimal results.

Some patients begin with Wegovy due to lower cost and switch to Mounjaro if weight loss plateaus or proves insufficient. Others start directly with Mounjaro to maximise early results. Neither approach is inherently superior — the best choice is the one you'll adhere to consistently for 12–18 months, as both medications require long-term use to maintain weight loss. Discontinuation typically results in weight regain, making sustainability a key consideration.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  3. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 [accessed 13 August 2026]
  4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
  5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors. Mounjaro and Wegovy do not cure obesity and are intended for long-term weight management in conjunction with a reduced-calorie diet and increased physical activity.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Is Mounjaro more effective than Wegovy for weight loss?
Clinical trial data shows Mounjaro (tirzepatide) achieved an average 22.5% body weight reduction compared to 14.9% with Wegovy (semaglutide) over similar timeframes. However, individual responses vary, and your UK prescriber will recommend the most suitable option based on your medical history and weight loss goals.
Can I switch from Wegovy to Mounjaro or vice versa?
Yes, switching between treatments is possible under prescriber supervision. Your UK clinician will determine the appropriate starting dose and monitor your response during the transition, as cross-tolerance between GLP-1 medications may affect initial efficacy.
Which has fewer side effects: Mounjaro or Wegovy?
Both medications have similar side effect profiles, with nausea, diarrhoea, and vomiting being most common during dose escalation. Discontinuation rates due to adverse effects are comparable (6–7%), suggesting neither treatment has a clear tolerability advantage across all patients.
How long does it take to see results with Mounjaro vs Wegovy?
Most patients notice appetite reduction within 1–2 weeks of starting either medication, with measurable weight loss evident by week 4. Maximum effects typically occur after reaching maintenance doses at 16–20 weeks, with continued weight reduction over 12–18 months when combined with lifestyle changes.
Do I need a prescription for Mounjaro or Wegovy in the UK?
Yes, both Mounjaro and Wegovy are prescription-only medications in the UK. Cured Pharmacy provides a free online consultation with UK-registered prescribers, who will assess your suitability and issue a prescription if clinically appropriate.
Can I use Mounjaro or Wegovy if I have type 2 diabetes?
Both medications are licensed for weight management in adults with or without type 2 diabetes. In fact, tirzepatide is also licensed separately (as Mounjaro) for diabetes management. Your prescriber will adjust doses of any existing diabetes medications to prevent hypoglycaemia when starting treatment.
What happens if I stop taking Mounjaro or Wegovy?
Clinical trials show most patients regain weight after discontinuing GLP-1 medications, typically returning to 50–80% of their original weight within 12 months. Both treatments are designed for long-term use, and your prescriber will discuss maintenance strategies to preserve weight loss results.
Are Mounjaro and Wegovy available on the NHS?
NHS access is limited to specialist weight management services in most UK regions, with strict eligibility criteria. Private online pharmacies like Cured Pharmacy offer faster access with transparent pricing, free consultations, and discreet home delivery for patients who don't meet NHS criteria or prefer private treatment.
What does the UK clinical evidence show about Mounjaro vs Wegovy?
Clinical trials show Mounjaro (tirzepatide) delivers superior weight loss compared to Wegovy, with patients losing an average of 21% body weight versus 15% with semaglutide. Cured Pharmacy provides both treatments with UK-registered prescriber consultations to help you choose the right option based on clinical evidence.
Is Mounjaro approved by UK regulators like Wegovy?
Yes, Mounjaro is MHRA-approved for weight management in the UK, just like Wegovy. Both medications have undergone rigorous clinical trials and are prescribed through licensed UK pharmacies like Cured Pharmacy following a medical consultation.
Can I switch from Wegovy to Mounjaro mid-treatment?
Yes, many patients switch from Wegovy to Mounjaro based on clinical results and tolerability. Cured Pharmacy's UK-registered prescribers can assess your current treatment and provide guidance on safely transitioning between medications with proper dose titration.
How does Mounjaro pricing compare to Wegovy at UK pharmacies?
Mounjaro starts at £124.99 for the 2.5mg dose at Cured Pharmacy, while Wegovy begins at £69 for the 0.25mg starter dose. Although Wegovy appears cheaper initially, Mounjaro often provides better value due to superior clinical outcomes and potentially shorter treatment duration.
Does the clinical evidence support combining Mounjaro and Wegovy?
No, UK clinical guidelines do not support combining Mounjaro and Wegovy as both are GLP-1 receptor agonists with overlapping mechanisms. Cured Pharmacy prescribers will only recommend one medication at a time based on your individual clinical needs and the latest evidence.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.